Emerging Business Models in the Pharmaceutical Industries ...
Emerging Business Models in the Pharmaceutical Industries ...
Emerging Business Models in the Pharmaceutical Industries ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
New Revenue <strong>Models</strong><br />
New revenue models are favor<strong>in</strong>g pharma companies<br />
despite <strong>the</strong> fall of block busters. Pharma companies need<br />
to significantly cut down <strong>the</strong>ir costs, by as much as 13.5%<br />
of <strong>the</strong> revenues, and offset future loss of revenues caused<br />
by withdraw<strong>in</strong>g block busters.<br />
Added revenues contributed by price hikes, semi block<br />
busters <strong>in</strong> <strong>the</strong> form of NMEs, brand equalisation, generic<br />
buy back, and overall market growth will fur<strong>the</strong>r add to<br />
total revenues.<br />
W<strong>in</strong>n<strong>in</strong>g Proposition<br />
The w<strong>in</strong>n<strong>in</strong>g proposition will come <strong>in</strong> <strong>the</strong> form of short and<br />
long term strategies.<br />
Short term strategies are ma<strong>in</strong>ly geared towards pre- and<br />
post-patent expiry directives, and <strong>the</strong> launch of semi block<br />
busters.<br />
Long term strategies revolve around owned health care<br />
kiosks and consistent improvement <strong>in</strong> efficiency and cost<br />
reduction with <strong>the</strong> help of <strong>the</strong> <strong>in</strong>tegrated network model.<br />
Conclusions<br />
Strategic Analysis of <strong>the</strong> Pharma Market, Future Revenue <strong>Models</strong> and Key Players 80
Change language